{"id":"NCT02334748","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies","officialTitle":"A French Open-label Extension Study of Canakinumab in Patients Who Participated in International Phase III Studies CACZ885G2301E1 or CACZ885G2306 in Systemic Juvenile Idiopathic Arthritis and CACZ885N2301 in Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11-03","primaryCompletion":"2018-08-31","completion":"2018-08-31","firstPosted":"2015-01-08","resultsPosted":"2020-05-19","lastUpdate":"2020-05-19"},"enrollment":31,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Systemic Juvenile Idiopathic Arthritis","Hereditary Periodic Fevers"],"interventions":[{"type":"DRUG","name":"canakinumab","otherNames":[]}],"arms":[{"label":"canakinumab","type":"EXPERIMENTAL"}],"summary":"The objective of this extension protocol is to collect safety data (serious and non-serious adverse events) and to provide continuous canakinumab to patients in France who completed study CACZ885G2301E1(NCT00891046), CACZ885G2306 (NCT02296424) or CACZ885N2301 (NCT02059291) until a decision regarding reimbursement in France is effective for canakinumab (IlarisÂ®) in these indications.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"every 4 weeks up to 1 year","effectByArm":[{"arm":"Canakinumab","deltaMin":7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":2},"locations":{"siteCount":3,"countries":["France"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":31},"commonTop":["Nasopharyngitis","Arthralgia","Pyrexia","Gastroenteritis","Abdominal pain"]}}